VX-745 is primarily used in research settings as a selective inhibitor of p38 mitogen-activated protein (MAP) kinase, a key enzyme involved in inflammatory signaling pathways. It has been investigated for its potential to modulate immune responses and reduce inflammation, making it a compound of interest in studies related to autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. Due to its ability to cross cell membranes effectively, VX-745 is useful in cellular and in vivo models to probe p38 MAPK-dependent processes. Its application remains confined to preclinical research, where it helps elucidate the role of p38 signaling in disease mechanisms and therapeutic intervention.